PURA Announces New West Coast Distributor For EVERx CBD Sports Water
June 12 2019 - 1:24PM
InvestorsHub NewsWire
DALLAS, TX -- June 12, 2019 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) today announced signing a new West Coast
Distributor for its EVERx CBD Sports Water. The distributor is
headquartered in Oregon. PURA currently has over $1 million in
annualized revenue primarily from the sales of its EVERx CBD
Sports Water. Sales of EVERx today come primarily from the South
and South West United States. PURA recently announced signing a new
East Coast Distributor as well. PURA has announced
a 2019 $4 million revenue
target.
PURA Speculative
Buy Recommendation and $0.25 PPS Target w/Potential to
$0.35
Goldman Small Cap Research has released a
new research report recommending PURA as a Speculative BUY with a $0.25 PPS Target.
Goldman Small Cap Research further reports that the shares of PURA
“have the potential to reach the $0.35 mark.” The report
highlights PURA’s growing EVERx CBD Sports Water sales and the
coming introduction of new beverages as well as the potential for
the company to exceed its 2019 sales targets through the pending
doubling of its production capacity and through planned
acquisitions. The report further details recent updates
intended to accelerate the issue of Nouveau (USOTC:
NOUV) stock to PURA shareholders in a dividend distribution.
Notably, the report points to the capacity and quality
improvements enabled by the addition of a new team member with
exceptional beverage industry professional
experience.
For more information on Puration,
visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news release contains forward-looking
statements within the meaning of the Securities Litigation Reform
Act. The statements reflect the Company's current views with
respect to future events that involve risks and uncertainties.
Among others, these risks include the expectation that any of the
companies mentioned herein will achieve significant sales, the
failure to meet schedule or performance requirements of the
companies' contracts, the companies' liquidity position, the
companies' ability to obtain new contracts, the emergence of
competitors with greater financial resources and the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Sep 2023 to Sep 2024